psychiatric

Seizing the MTM Opportunity:
What Psychiatric Pharmacists Need to Know

This presentation will focus on how the health care system is changing and how psychiatric pharmacists need to adapt to these changes to be successful.  The objectives for the presentation will be to; a) understand the changing environment, b) adopt terminology that has currency in the new system, c) understand the new rules and regulations, d) be able to recognize success under the new rules, and e) decide which direction for the future is best.  The specific changes that impact psychiatric pharmacists will be presented and the consequences of these changes discussed. Read more about this session.

2010-2011 Psychiatric Pharmacy Review Course - ACPE Credit Only

The Psychiatric Pharmacy Review Course (Review Course) is an excellent course of study and resource for those seeking a review of psychopharmacology and current standards of care. Read more about this session.

Clozapine monitoring after discontinuation

We had this issue come up at our hospital this week, and we just wanted to hear others’ thoughts on the topic.  The package insert of clozapine states “When treatment with clozapine is discontinued (regardless of the reason), WBC ...

psychiatric emergency in the era of injectable benzodiazpine drug shortages

Anyone else have cases where IM benzo drug shortages contribute to less than optimal outcomes (not potential but real).  We had one yesterday.   I’d like to exchange info off list.  We’re considering a case report or ...

Metabolic syndrome monitoring -baseline

Wondering how others that are monitoring metabolic syndrome define "baseline" for patients admitted to your facility already on a SGA. Do you r etrospectively try to find the weight prior to starting the medication or do you just ...

2012 Annual Meeting Pre-Meeting Workshop Preview Available Through Complimentary CPNP University Course

CPNP’s 2011 Annual Meeting keynote speaker Linda Strand, PharmD, PhD, provided a motivating, can-do view of healthcare reform legislation and the opportunities available to pharmacists.

Recognizing Movement Disorders: Reviving Old Practices

Robin Hieber, Pharm.D., BCPP

Movement disorders have many different presentations and are defined as a group of syndromes that affect the ability for one to control movement in a given muscle or muscle group. Many of the medications we use to treat psychiatric illness (antipsychotics, lithium, and valproic acid) have the potential to cause movement disorders, often referred to as extrapyramidal side effects, though predictability is lacking. Antipsychotic-induced dopamine blockade can lead to acute dystonia, akathisia, and Parkinsonism, all of which are generally reversible if treatment is discontinued.

Applied Monitoring for Tardive Dyskinesia and Other Extrapyramidal Side Effects

John E. Kalachnik, M.Ed.
Woodward Resource Center
Iowa Department of Human Services
Woodward, IA 

Note: The author does not represent the State of Iowa nor its policies, procedures, or positions.

The 2012 Annual Meeting will feature John Kalachnik, M.Ed., providing a 1-hour overview of drug-induced movement disorders, rating scales and applied monitoring. This will be followed by a 1 hour learning lab session allowing for hands-on experience in utilizing common rating scales used to assess movement disorders. Kalachnik is the Director of Integrated Services for the Woodward Resource Center and is one of the original authors of the Dyskinesia Identification System-Condensed User Scale (DISCUS). Register for the 2012 Annual Meeting now and plan to attend this excellent programming.

Identifying false, but apparently plausible, explanations for the onset of psychiatric disorder

Identifying false, but apparently plausible, explanations for the onset of psychiatric disorder

Molecular Psychiatry 17,
7 (January 2012). doi:10.1038/mp.2011.72

Author: D L Foley

Levels of explanation in psychiatric and substance use disorders: implications for the development of an etiologically based nosology

Levels of explanation in psychiatric and substance use disorders: implications for the development of an etiologically based nosology

Molecular Psychiatry 17,
11 (January 2012). doi:10.1038/mp.2011.70

Author: K S Kendler

This page may contain content contributed by CPNP members or aggregated from other online sources. This content is provided as an unmoderated service to members for civil discussion and collaboration. Any opinions, conclusions, or recommendations are those of the author. If you come across any abuse or violation of the terms of use, please report the abuse.